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i.org/1diabetes mellitus (DM) is unknown. Our objective was to determine if a panel of 18
biomarkers previously associated with risk of cardiovascular disease also predicts incident
DM in statin-treated patients with coronary artery disease (CAD). The Treating to New
Targets (TNT) study is a randomized trial that compared the efﬁcacy of high (80 mg) versus
low (10 mg) dose atorvastatin for the secondary prevention of coronary heart disease events.
Fasting plasma levels of standard lipids and of 18 emerging CAD risk biomarkers were
obtained after an 8-week run-in period on atorvastatin 10 mg in a random sample of 1,424
TNT patients. After exclusion of patients with DM at baseline (n [ 253), 101 patients
developed DM during the median follow-up of 4.9 years. Patients with incident DM had
lower levels of total and high-molecular weight adiponectin, lipoprotein-associated phos-
pholipase A2 (Lp-PLA2), soluble receptor of advanced glycation end products, and vitamin
D compared with patients without incident DM. In contrast, insulin, soluble CD40 ligand,
and soluble intercellular adhesion molecule-1 levels were higher in patients with incident
DM compared with those without. Plasma levels of C-reactive protein, cystatin C,
lipoprotein(a), monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperox-
idase, neopterin, N-terminal fragment of proeB-type natriuretic peptide, osteopontin, and
soluble vascular cell adhesion molecule-1 were comparable in patients with and without
incident DM. After multivariate adjustment, total and high-molecular weight adiponectin
as well as Lp-PLA2 were negatively associated with incident DM. Results of this study
suggest that plasma lipids and some emerging CAD risk biomarkers, such as adiponectin
and Lp-PLA2, may be useful for predicting incident DM in statin-treated patients with
stable CAD.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:494e498)The prevalence of type 2 diabetes mellitus (DM) is
increasing in the vast majority of countries around the
world.1 Patients who already cope with chronic diseases
such as cardiovascular disease (CVD) are at increased risk
of developing type 2 DM.2 We and others have previously
documented that traditional risk factors such as hypertension
and obesity, as well as triglyceride and high-density
lipoprotein (HDL) cholesterol levels are associated with
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0.1016/j.amjcard.2016.05.044We have also recently shown that plasma levels of some
emerging biomarkers of lipoproteinelipid metabolism,
inﬂammation, and glucoseeinsulin homeostasis may predict
CVD risk in statin-treated patients with CAD.4 Whether
these emerging CVD risk biomarkers are also associated
with incident DM and whether they have any clinical value
in such patients are unknown. The objective of the present
study was to determine whether a panel of 18 biomarkers
associated with the risk of CVD also predicted incident DM
in statin-treated patients with CAD.
Methods
The study protocol and outcome measures for the
Treating to New Targets (TNT) study have been published
previously.5 In brief, patients with clinically manifest CAD
commenced 8 weeks of open-label treatment with atorvas-
tatin 10 mg/day. After this run-in period, 10,001 patients
with low-density lipoprotein cholesterol levels <130 mg/dl
(<3.4 mmol/L) were randomized in a double-blind design to
therapy with either 10 mg or 80 mg of atorvastatin per day
and followed for a median of 4.9 years. Incident DM was
deﬁned prospectively as at least 2 postbaseline fasting bloodwww.ajconline.org
Table 1
Baseline characteristics of patients with diabetes mellitus at baseline and in patients with and without incident diabetes mellitus during follow-up in the TNT
study
Baseline
Follow-up
Diabetes Mellitus
No Yes
(N¼253)
Without incident
DM (N¼1070)
With incident DM
(N¼101)
Atorvastatin 80 mg 528 (49.4%) 56 (55.5%) 123 (48.6)
Men 872 (81.5%) 80 (79.2%) 186 (73.5%)*
White 1013 (94.7%) 92 (91.1%) 228 (90.1%)*
Age (years) 60.99.0 61.18.0 64.07.8*†
Body mass index (kg/m2) 27.94.0 31.04.9* 31.05.6*
Systolic blood pressure (mmHg) 129.416.1 133.915.9* 135.318.0*
Diastolic blood pressure (mmHg) 77.69.0 78.58.0 76.210.3*†
Hypertension 566 (52.9%) 53 (52.5%) 193 (76.3%)*†
Smoker
Current 11 (10.9%) 155 (14.5%) 15 (5.9)*
Past 72 (71.3%) 652 (60.9)* 176 (69.6)*
Never 18 (17.8%) 263 (24.6) 62 (24.5)
Metabolic syndrome 506 (47.3%) 78 (77.2)* 210 (83.0)*
Estimated glomerular ﬁltration rate (mL/min/1.72 m2) 64.9  10.8 64.7  11.3 63.6  12.9
Angiotensin-converting-enzyme inhibitors 561 (53.8%) 49 (49.5%) 145 (58.7%)
Angiotensin II receptor blockers 170 (16.3%) 16 (16.2%) 35 (14.2%)
Beta blockers 727 (69.8%) 64 (64.6%) 172 (69.6%)
Calcium channel blockers 412 (39.5%) 34 (34.3%) 103 (41.7%)
Antiplatelets 146 (14.0%) 9 (9.1%) 43 (17.4%)
Vitamin K antagonists 162 (15.5%) 20 (20.2%) 39 (15.8%)
Other anticoagulants 6 (0.6%) 0 (0%) 0 (0%)
Aspirin 957 (91.8%) 84 (84.8%) 226 (91.5%)
Data are shown as n (%) for categorical variables and mean  SD for continuous variables.
* Signiﬁcantly different than patients without incident diabetes.
† Signiﬁcantly different than patients with incident diabetes; p <0.05.
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baseline fasting blood glucose measurement >2 mmol/L
above baseline. We also included patients for whom inci-
dent DM was identiﬁed through adverse event reporting.
Only patients from whom informed consent was obtained
for measuring nonlipid biomarkers (in addition to that
originally collected for the primary study) were selected for
this substudy. Biomarker concentrations were measured in a
random sample of 1,424 patients. Biomarkers concentra-
tions were measured in fasting plasma samples collected at
the time of randomization (after the 8-week atorvastatin
10 mg run-in period) and again 1 year after randomization.
The biomarkers were selected based on previous studies
linking them with cardiovascular risk and were selected in
such a way that they represent speciﬁc biologic pathways
associated with CVD. For instance, systemic inﬂammation
is represented by C-reactive protein (CRP), macrophage
recruitment/activity is represented by monocyte chemotactic
protein-1, neopterin, soluble intercellular adhesion
molecule-1, and soluble vascular cell adhesion molecule-1,
oxidative stress is represented by myeloperoxidase and
lipoprotein-associated phospholipase A2 (Lp-PLA2), tissue
remodeling is represented by matrix metalloproteinase-9,
and osteopontin, platelet activation/thrombosis is repre-
sented by soluble CD40 ligand and lipoprotein(a), insulin
resistance is represented by insulin, adiponectin,
high-molecular weight (HMW) adiponectin, HMW/totaladiponectin (ratio), receptor for advanced glycation
endproducts and vitamin D, congestive heart failure is rep-
resented by N-terminal fragment of proeB-type natriuretic
peptide and kidney function by cystatin C. The methods
used for the measurements of lipid and nonlipid biomarkers
as well as the differences in biomarkers levels between
baseline and one year have been published previously.4 The
study was approved by the local research ethics committee
or institutional review board at each center.
Patient characteristics at baseline were compared across 3
patients groups: those without DM at baseline who did not
have incident DM, those without DM at baseline who did
have incident DM, and those who had DM at baseline. A
chi-square test was used for categorical variables, and a
Wilcoxon rank-sum test for continuous variables. The
association between on-treatment lipids and biomarker
levels (at time of randomization), and incident DM
was assessed in Cox proportional hazard analyses after
adjustment for age, gender, treatment arm, smoking,
hypertension, body mass index (BMI), and HDL cholesterol
and triglyceride levels, using time to primary end point as
the dependent variable.
Results
The clinical characteristics of the 3 study groups are
presented in Table 1. Patients with incident DM during
Table 2
Lipid and nonlipid biomarker levels measured at randomization in patients with diabetes at baseline and in patients with and without incident diabetes during
follow-up
Baseline
Follow-up
Diabetes Mellitus
No Yes
(N¼253)
Without incident DM
(N¼1070)
With incident DM
(N¼101)
Total cholesterol 17424 mg/dL (4.510.61 mmol/L) 18027 mg/dL (4.670.70 mmol/L)* 17625 mg/dL (4.540.64 mmol/L)
LDL cholesterol 9717 mg/dL (2.520.45 mmol/L) 9920 mg/dL (2.560.51 mmol/L) 9618 mg/dL (2.470.47 mmol/L)
HDL cholesterol 4811 mg/dL (1.240.29 mmol/L) 4611 mg/dL* (1.180.29 mmol/L)* 4410 mg/dL* (1.150.27 mmol/L)*
Total/HDL cholesterol 3.80  0.85 4.09  0.87* 4.12  0.97*
Triglycerides 133 (101-174) mg/dL
(1.50 [1.14e1.96] mmol/L)
154 (120-218) mg/dL*
(1.74 [1.35e2.46] mmol/L)*
162 (120-221) mg/dL*
(1.83 [1.35e2.50] mmol/L)*
Total adiponectin (mg/mL) 6.75 (4.92e9.54) 5.19 (4.26e7.30)* 6.12 (4.43e9.85)*†
HMW adiponectin (mg/mL) 2.02 (1.21e3.26) 1.45 (1.01e2.01)* 1.80 (1.14e2.87)†
C-reactive protein (mg/L) 1.57 (0.72e3.56) 1.77 (0.76e4.16) 2.10 (0.95e4.58)*
Cystatin C, (mg/mL) 0.77 (0.67e0.90) 0.80 (0.69e0.91) 0.81 (0.67e0.97)*
Insulin (mU/mL) 11 (8e15) 15 (11e20)* 16 (12e27)*†
Lipoprotein(a) (mg/dL) 15 (5e40) 14 (5e34) 13 (4e41)
Lipoprotein-associated
phospholipase A2 (ng/mL)
335 (275e395) 310 (237e356)* 305 (241e355)*
Monocyte chemoattractant
protein-1 (pg/mL)
98 (74e129) 99 (76e134) 107 (81e147)*
Matrix metalloproteinase-9 (ng/mL) 43.6 (29.8e66.1) 46.0 (30.8e83.4) 43.5 (29.8e68.2)
Myeloperoxidase (ng/mL) 21.3 (10.1e56.3) 19.6 (10.1e50.8) 23.8 (11.0e60.5)
Neopterin (ng/mL) 2.85 (2.30e3.50) 2.80 (2.10e3.62) 3.10 (2.54e3.83)*†
N-terminal pro-B-type
natriuretic peptide (fmol/mL)
510.4 (405.0e649.2) 506.7 (392.1e621.8) 512.9 (404.8e668.5)
Osteopontin (ng/mL) 46.2 (32.3e58.8) 45.4 (30.1e59.6) 48.2 (35.1e63.2)
Soluble receptor for advanced
glycation end products (ng/mL)
1.34 (1.02e1.80) 1.22 (0.94e1.60)* 1.33 (1.02e1.79)†
soluble CD40 ligand (ng/mL) 3.87 (1.86e9.21) 5.69 (2.51e11.4)* 4.13 (2.16e10.8)
soluble intracellular adhesion
molecule-1 (ng/mL)
140 (104e182) 160 (114e202)* 149 (114e195)*
soluble vascular cell adhesion
molecule-1 (mg/mL)
1.04 (0.86e1.26) 1.11 (0.92e1.26) 1.09 (0.90e1.32)*
Vitamin D, ng/mL 77.0 (76.0e79.0) 71.5 (67.0e80.0)* 69.0 (65.0e75.0)*
Data are shown as mean  SD for standard lipids and as median (interquartile range) for triglycerides and biomarkers.
* Signiﬁcantly different than patients without incident diabetes.
† Signiﬁcantly different than patients with incident diabetes; p <0.05.
496 The American Journal of Cardiology (www.ajconline.org)follow-up and those with DM at baseline had a higher mean
BMI, mean systolic blood pressure, and higher prevalence
of metabolic syndrome than those without DM at baseline
and without incident DM during follow-up. These differ-
ences in clinical characteristics of study patients who
did versus those who did not develop incident DM were
comparable to what we have previously reported in the
entire TNT study population.3
Plasma levels of lipid and nonlipid biomarkers in these
patients are presented in Table 2. Patients with incident DM
had higher levels of triglycerides and total cholesterol levels
and lower levels of HDL cholesterol compared with patients
without incident DM. They were also characterized by a
higher total cholesterol/HDL cholesterol ratio. With regards
to nonlipid biomarkers, patients with incident DM had lower
levels of total and HMW adiponectin, Lp-PLA2, soluble
receptor of advanced glycation end products, and vitamin D
compared with patients without incident DM. However,
insulin, soluble CD40 ligand, and soluble intercellular
adhesion molecule-1 levels were higher in patients with
incident DM compared with patients without incident DM.Plasma levels of low-density lipoprotein cholesterol, high
sensitivity CRP, cystatin C, lipoprotein(a), monocyte
chemotactic protein-1, matrix metalloproteinase-9, myelo-
peroxidase, neopterin, N-terminal fragment of proeB-type
natriuretic peptide, osteopontin, and soluble vascular cell
adhesion molecule-1 were comparable in patients with
versus without incident DM.
We next investigated the relation between nonlipid
biomarkers levels and incident DM per 50% decrease in
biomarker levels for incidentDM.Results presented inFigure1
show that after adjusting for age, gender, treatment arm,
smoking, hypertension, BMI,HDLcholesterol and triglyceride
levels, total and HMW adiponectin as well as Lp-PLA2 were
negatively associated with risk of incident DM. Further
adjustment for angiotensin-converting enzyme inhibitors and
beta-blocker use did not change the reported associations.
Discussion
Our results suggest that plasma levels of several
emerging biomarkers are either higher or lower in patients
0 1 2 3
Vitamin D
sVCAM-1
sICAM-1
sCD40L
sRAGE
Osteopontin
NT-pro-BNP
Neopterin
Myeloperoxidase
MMP-9
MCP-1
Lp-PLA2
Lipoprotein(a)
Insulin
Cystatin
C-reactive protein
HMW adiponectin
Adiponectin
Hazard ratio (95% CI) for incident diabetes
Figure 1. Hazard ratios (95% CIs) per 50% decrease of biomarker for risk of
developing incident DM. Hazard ratios are adjusted for age, gender,
treatment arm, smoking, hypertension, BMI, and HDL cholesterol and
triglyceride levels. MCP-1 ¼ monocyte chemotactic protein-1; MMP-9 ¼
matrix metalloproteinase-9; NT-pro-BNP¼ N-terminal fragment of proeB-
type natriuretic peptide; sRAGE ¼ soluble receptor of advanced glycation
end products; sCD40 L ¼ soluble CD40 ligand; sICAM-1 ¼ soluble
Intercellular adhesion molecule-1; and sVCAM-1 ¼ soluble vascular cell
adhesion molecule-1.
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DM. However, after adjusting for DM risk factors, we found
that only adiponectin and Lp-PLA2 remained independently
associated with incident DM.
Many studies have tested the hypothesis that circulating
biomarkers may predict incident DM.6 However, very few,
if any, have tested this hypothesis in statin-treated patients
with CAD. A large-scale meta-analysis had previously
reported a signiﬁcant association between low adiponectin
levels and incident DM.7 Our results extend these ﬁndings
to statin-treated patients with CAD. However, the causality
of adiponectin in predicting DM risk has recently been
questioned by a large-scale Mendelian randomization
study.8 Although the negative association between
Lp-PLA2 and DM incidence is somewhat unexpected,
previous cross-sectional studies have documented a negative
association between Lp-PLA2 and markers of the glucose-
einsulin homeostasis in patients with vascular disease.9 In
DM-prone rats, injections of recombinant Lp-PLA2 reduced
the incidence of DM.10 The impact of the Lp-PLA2 inhib-
itor daraplabib on cardiovascular outcomes was recently
tested in 2 large-scale phase 3 trials in patients with acute
coronary syndrome11 and stable vascular disease.12 In both
these studies, darapladib was shown not to reduce the risk
of cardiovascular, and there was no apparent effect of
darapladib on DM incidence. Therefore, the relation of
Lp-PLA2 to DM risk also needs to be further studied.
To our knowledge, our study is the ﬁrst to investigate therelation between CRP and incident DM in patients with
established CAD treated with statins. In contrast to primary
prevention studies performed in middle-aged men13 and
women,14 our results suggest that there is no association
between CRP and incident DM in this population.
Our study has limitations. For instance, biomarkers were
not measured in the entire TNT study population. Therefore,
our conclusions are based on relatively few incident DM
cases. In this study, levels of lipid and nonlipid biomarkers
were measured at randomization, when all subjects had
already been on 10 mg atorvastatin treatment for at least
8 weeks. It was therefore not possible to investigate the
relation between biomarkers level off-statin therapy with
DM incidence. For both of these reasons, it was not possible
to identify biomarkers that could potentially explain the
possible increased risk of DM associated with statin therapy.
It should also be considered that only BMI and not waist
circumference was measured in these participants. Waist
circumference may have had a bigger inﬂuence on the as-
sociation between biomarkers and incident DM than BMI,
especially adiponectin. In addition, most study participants
included in TNT were Caucasians. These results may
therefore not be applicable to other ethnicities. In conclu-
sion, results of this study suggest that plasma lipids and
some emerging CAD risk biomarkers, such as adiponectin
and Lp-PLA2, may be useful for predicting incident DM in
statin-treated patients with stable CAD. Additional studies
validating the clinical usefulness of these biomarkers
are warranted.
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